Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Linker Chemistry in Radiopharmaceutical Design.

Bioconjugate chemistry·2026

Same author

Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same author

Pharmacokinetic Optimization of Radiocopper-Based Theranostic Pretargeting.

Molecular pharmaceutics·2026

Same author

Harnessing Frémy's salt for tyrosine-directed bioconjugations.

RSC advances·2026

Same author

Harnessing Fc-Directed Bioconjugation for the Synthesis of Site-Specifically Modified Radioimmunoconjugates.

Bioconjugate chemistry·2025

Same author

Exploring Auger electron-emitting radionuclides for targeted DNA damage in mismatch repair-deficient cells: a theoretical study of <sup>99</sup>Rh- and <sup>123</sup>I-labeled metalloinsertors.

International journal of radiation biology·2025

Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Evaluating Radiotheranostic Targets for Endometrial Cancer.

Joni Sebastiano^1,2,3, Shane A McGlone¹, Zachary V Samuels^1,2,4

¹Department of Chemistry, Hunter College, City University of New York, New York, New York.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|August 21, 2025

Summary

This summary is machine-generated.

New immuno-PET probes targeting human epidermal growth factor receptor 2 (HER2) and CD24 show promise for imaging endometrial cancer. These agents may aid in noninvasive staging and monitoring of the disease.

Keywords:

CD24 HER2 MUC16 PET endometrial cancer radiopharmaceuticals

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Related Experiment Videos

Last Updated: Sep 10, 2025

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Area of Science:

Oncology
Radiochemistry
Molecular Imaging

Background:

Endometrial cancer is a common gynecologic malignancy with increasing incidence and mortality.
Limited targeted therapies exist for advanced or recurrent endometrial cancer, necessitating improved diagnostic tools.
Biomarkers such as human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24 are explored as potential targets.

Purpose of the Study:

To investigate HER2, MUC16, and CD24 as potential radiotheranostic targets for endometrial cancer.
To develop and evaluate novel immuno-positron emission tomography (immuno-PET) probes for endometrial cancer detection.

Main Methods:

Immunocytochemical and immunofluorescence staining assessed biomarker expression in cancer and healthy cells/tissues.
Monoclonal antibodies targeting HER2, MUC16, and CD24 were conjugated with deferoxamine (DFO) and radiolabeled with Zirconium-89 ([89Zr]).
In vivo PET imaging and biodistribution studies were conducted in murine models of endometrial cancer.

Main Results:

Endometrial cancer cells and tissues showed elevated expression of HER2, MUC16, and CD24 compared to controls.
The developed immuno-PET probes ([89Zr]Zr-DFO-trastuzumab, [89Zr]Zr-DFO-AR9.6, [89Zr]Zr-DFO-ATG-031) were successfully synthesized with high purity and specific activity.
The CD24-targeted probe ([89Zr]Zr-DFO-ATG-031) and the HER2-targeted probe ([89Zr]Zr-DFO-trastuzumab) demonstrated significant tumor uptake and contrast in preclinical models.

Conclusions:

The immuno-PET probes targeting CD24 and HER2 show significant potential for noninvasive imaging of endometrial cancer.
These probes could facilitate disease staging, monitoring, and serve as companion agents for targeted therapies.
Further clinical evaluation is warranted to confirm the utility of these radiotheranostic agents.